Verastem Oncology's CEO comments on a volatile week and #ASCO24 data in pancreatic cancer
Dan Paterson gives background on the rolling submission the company started this week in a type of ovarian cancer, with his thoughts on the market reaction, and highlights new data at ASCO this year.